



(51) International Patent Classification:

C12N 9/22 (2006.01) C12N 15/90 (2006.01)
C12N 15/63 (2006.01) C12N 15/864 (2006.01)

(21) International Application Number:

PCT/US2021/062714

(22) International Filing Date:

09 December 2021 (09.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/123,112 09 December 2020 (09.12.2020) US
63/235,638 20 August 2021 (20.08.2021) US

(71) Applicant: **SCRIBE THERAPEUTICS INC.** [US/US];
1150 Marina Village Parkway, Alameda, California 94501 (US).

(72) Inventor; and

(71) Applicant: **MOHR, Manuel** [DE/US]; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US).

(72) Inventors: **BANEY, Katherine**; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **SIDORE, Angus**; c/o Scribe Therapeutics

Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **FORTUNY, Cecile**; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **ADIL, Maroof**; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **WRIGHT, Addison**; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **STAAHL, Brett T.**; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **HIGGINS, Sean**; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **OAKES, Benjamin**; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **MAKHIIJA, Suraj**; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **DENNY, Sarah**; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US).

(74) Agent: **HARTMAN, Kenichi N.** et al.; 1299 Pennsylvania Avenue NW, Suite 700, Washington, District of Columbia 20004-2400 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

(54) Title: **AAV VECTORS FOR GENE EDITING**




FIG. 6

(57) Abstract: Provided herein polynucleotides configured for incorporation into recombinant adeno-associated virus (AAV) vectors. The polynucleotides encode for CRISPR proteins, gRNA, and ancillary components of AAV vectors useful in the modification of target nucleic acids. The systems are also useful for introduction into cells, for example eukaryotic cells having mutations in the target nucleic acid of a gene. Also provided are methods of using such AAV vectors to modify cells having such mutations.

HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*